EHA 2022 | BTK inhibitor-associated adverse events in patients with CLL
Barbara Eichhorst
• 20 Jun 2022
Barbara Eichhorst, MD, University of Cologne, Cologne, Germany, discusses BTK inhibitor-related adverse events in patients with chronic lymphocytic leukemia (CLL), comparing the toxicity profiles of non-specific BTK inhibitors and next-generation BTK inhibitors. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.
Disclosures
Dr Eichhorst receives honoraria for presentations and advisory board from several different pharmaceutical companies involved in targeted agents in CLL (Abbvie, BeiGene, BMS, Gilead, Janssen, MSD, Roche).
